ORCHID PHARMA
|
ORCHID PHARMA Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 6.51 | 88.29 | 18.17 | 11.35 | -0.48 |
| CEPS(Rs) | 35.21 | 113.20 | 25.30 | 26.96 | 7.38 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 993.34 | 986.56 | 230.58 | 168.72 | 158.61 |
| Tax Rate(%) | -1.84 | -7.94 | -3.39 | - | - |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 0.32 | 9.86 | 13.52 | 12.66 | 9.75 |
| EBIT Margin(%) | 1.60 | 9.64 | 13.26 | 13.24 | -4.19 |
| Pre Tax Margin(%) | 0.85 | 8.70 | 11.22 | 8.30 | -10.17 |
| PAT Margin (%) | 0.86 | 9.39 | 11.60 | 8.30 | -10.17 |
| Cash Profit Margin (%) | 4.37 | 12.39 | 15.66 | 16.52 | 5.38 |
| Performance Ratios | |||||
| ROA(%) | 0.49 | 7.22 | 6.84 | 4.73 | -4.85 |
| ROE(%) | 0.70 | 9.79 | 10.23 | 8.27 | -8.75 |
| ROCE(%) | 1.11 | 8.95 | 9.35 | 9.11 | -2.32 |
| Asset Turnover(x) | 0.57 | 0.77 | 0.59 | 0.57 | 0.48 |
| Sales/Fixed Asset(x) | 0.82 | 1.00 | 0.65 | 0.56 | 0.48 |
| Working Capital/Sales(x) | 2.82 | 2.37 | 1.54 | 5.16 | 3.90 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.22 | 1.00 | 1.54 | 1.80 | 2.10 |
| Receivable days | 108.72 | 71.64 | 91.49 | 105.72 | 99.89 |
| Inventory Days | 122.82 | 94.23 | 109.80 | 110.01 | 106.18 |
| Payable days | 147.58 | 115.57 | 152.17 | 162.30 | 161.59 |
| Valuation Parameters | |||||
| PER(x) | 73.48 | 8.80 | 57.52 | 33.87 | - |
| PCE(x) | 13.59 | 6.86 | 41.32 | 14.26 | 38.52 |
| Price/Book(x) | 0.48 | 0.79 | 4.53 | 2.28 | 1.79 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 0.77 | 0.82 | 6.31 | 2.81 | 2.54 |
| EV/Core EBITDA(x) | 13.50 | 6.46 | 36.42 | 18.03 | 22.34 |
| EV/EBIT(x) | 48.05 | 8.47 | 47.56 | 21.21 | -60.59 |
| EV/CE(x) | 0.51 | 0.67 | 3.96 | 1.83 | 1.55 |
| M Cap / Sales | 0.59 | 0.85 | 6.47 | 2.36 | 2.07 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -11.79 | 70.57 | 23.05 | 19.00 | 24.33 |
| Core EBITDA Growth(%) | -60.21 | 24.58 | 36.82 | 63.14 | -3.48 |
| EBIT Growth(%) | -85.33 | 24.02 | 23.29 | 476.02 | 45.54 |
| PAT Growth(%) | -91.90 | 37.98 | 72.07 | 197.10 | 40.26 |
| EPS Growth(%) | -92.63 | 385.84 | 60.13 | 2,474.06 | 98.33 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.20 | 0.10 | 0.12 | 0.48 | 0.41 |
| Current Ratio(x) | 1.89 | 2.16 | 3.04 | 1.35 | 1.60 |
| Quick Ratio(x) | 1.13 | 1.26 | 2.03 | 0.73 | 0.88 |
| Interest Cover(x) | 2.12 | 10.17 | 6.49 | 2.68 | -0.70 |
| Total Debt/Mcap(x) | 0.12 | 0.04 | 0.03 | 0.21 | 0.23 |
Compare Financial Ratios of peers of ORCHID PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| ORCHID PHARMA | ₹5,342.8 Cr | 8% | -12.9% | 19.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹422,991.0 Cr | 1.1% | -4.2% | 4.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹256,310.0 Cr | 7.5% | 1.3% | 45.7% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹173,604.0 Cr | 1.8% | -6.3% | 26.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹111,722.0 Cr | 9.3% | 9.5% | 4.3% | Stock Analytics | |
| CIPLA | ₹109,628.0 Cr | 1.5% | -2.3% | -17.3% | Stock Analytics | |
ORCHID PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ORCHID PHARMA | 8% |
-12.9% |
19.3% |
| SENSEX | 1.2% |
0.4% |
-12.2% |
You may also like the below Video Courses
